# Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

> **NCT01134250** · PHASE1,PHASE2 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 48 (actual)

## Conditions studied

- Solid Tumor
- Breast Cancer
- Metastatic Melanoma
- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** F16IL2 in combination with paclitaxel

## Key facts

- **NCT ID:** NCT01134250
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-06
- **Primary completion:** 2014-04-07
- **Final completion:** 2014-04-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134250, "Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01134250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*